Free Trial
OTCMKTS:BRTX

BioRestorative Therapies (BRTX) Stock Price, News & Analysis

$1.53
+0.02 (+1.32%)
(As of 09/6/2024 ET)
Today's Range
$1.51
$1.57
50-Day Range
$1.32
$1.98
52-Week Range
$1.03
$3.67
Volume
5,443 shs
Average Volume
979,865 shs
Market Capitalization
$10.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BRTX stock logo

About BioRestorative Therapies Stock (OTCMKTS:BRTX)

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

BRTX Stock Price History

BRTX Stock News Headlines

War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
10 Micro-Cap Healthcare Stocks Insiders Are Buying
BioRestorative Therapies Inc (BRTX)
War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Best Light Therapy Lamps for 2023
See More Headlines
Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/13/2024
Today
9/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Healthcare
Current Symbol
OTCMKTS:BRTX
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Net Income
$-18,500,000.00
Net Margins
-13,728.83%
Pretax Margin
-13,728.83%

Debt

Sales & Book Value

Annual Sales
$174,100.00
Book Value
$2.65 per share

Miscellaneous

Free Float
3,660,000
Market Cap
$10.36 million
Optionable
Not Optionable
Beta
63.47
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives


BRTX Stock Analysis - Frequently Asked Questions

How have BRTX shares performed this year?

BioRestorative Therapies' stock was trading at $1.7399 at the beginning of 2024. Since then, BRTX stock has decreased by 12.1% and is now trading at $1.53.
View the best growth stocks for 2024 here
.

How were BioRestorative Therapies' earnings last quarter?

BioRestorative Therapies, Inc. (OTCMKTS:BRTX) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.06. The company had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 120.47% and a negative net margin of 13,728.83%.

When did BioRestorative Therapies' stock split?

BioRestorative Therapies's stock reverse split on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), Vaxart (VXRT).

This page (OTCMKTS:BRTX) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners